Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company specializing in the discovery, development, and commercialization of medicines for diabetes, oncology, immunology, and neuroscience.

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best quality stocks to invest in now. Tom Lee, co-founder of Fundstrat Global Advisors ...

The global market for acute migraine treatment is on a steady growth trajectory, with sales expected to rise from USD 2,700.7 million in 2024 to USD 4,194.1 million by 2034, reflecting a CAGR of 4.5% ...

AbbVie and Eli ... at Lilly. "The current scheme has harmed innovation, with costs spiralling out of control, and the UK falling behind other major countries to be left as a global outlier ...

To revive clinical research in the UK we need to streamline systems and dismantle bureaucracy, writes Masud Husain Clinical research in the UK is now at a critical point. What used to be a shining ...

Redwire Corporation (NYSE: RDW, the "Company"), a leader in space infrastructure for the next generation space economy, today ...

The Philippines is not only known for its stunning landscapes and warm-hearted people but also for its brilliant minds that ...

China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline ... moving against Eli Lilly and Innovent Biologics ...

FoodBev Media is delighted to announce the winners of the prestigious World Food Innovation Awards 2025, celebrating ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...